Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Scientific Reports February 5, 2024 Alistair Niemeijer, Erwin Krediet, Jeanine Kamphuis et al. 50 citations
Abstract Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a...